AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2490928 — intervention group
Group type: EXPERIMENTAL
Intervention: Low concentration mouthwash (0.04% sodium chloride, comparably activated)
Number of subjects: 18
Study 2490928 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash (activating system alone)
Number of subjects: 18
Study 776350 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa 750 mg/day combined with propranolol 240 mg/day
Number of subjects: 24
Study 776350 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa 750 mg/day combined with practolol 600 mg/day
Number of subjects: 24
Study 776350 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa 750 mg/day
Number of subjects: 24
Study 776350 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 240 mg/day
Number of subjects: 24
Study 776350 — intervention group
Group type: COMPARATOR
Intervention: Practolol 600 mg/day
Number of subjects: 24
Study 776350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30905211 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program for asthma care
Number of subjects: 78
Study 30905211 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 78
Study 30905211 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS/LABA treatment
Number of subjects: 78
Study 31331193 — intervention group
Group type: EXPERIMENTAL
Intervention: Anacetrapib 100 mg daily
Number of subjects: 19210
Study 31331193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19210
Study 31331193 — intervention group
Group type: EXPERIMENTAL
Intervention: Anacetrapib
Number of subjects: 19210
Study 27796852 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress myocardial perfusion imaging (MPI)
Number of subjects: 303
Study 27796852 — intervention group
Group type: COMPARATOR
Intervention: Coronary computed tomographic angiography (CCTA)
Number of subjects: 303
Study 25875383 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (NTG) doses of 10, 20, 30, and 40 μg
Number of subjects: 24
Study 25875383 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow-mediated dilatation (FMD)
Number of subjects: 24
Study 24228630 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-help intervention combined with chat counseling
Number of subjects: 0
Study 24228630 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-help intervention alone
Number of subjects: 0
Study 24228630 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 0
Study 21865363 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol‐cyproterone acetate (EE‐CA)
Number of subjects: 34
Study 21865363 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose pioglitazone-flutamide-metformin (PioFluMet)
Number of subjects: 34
Study 19262436 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (1.25 mg/0.05 mL) before PRP
Number of subjects: 41
Study 19262436 — intervention group
Group type: COMPARATOR
Intervention: Panretinal photocoagulation (PRP) alone
Number of subjects: 41
Study 17407624 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination brimonidine-timolol (FCBT)
Number of subjects: 30
Study 17407624 — intervention group
Group type: COMPARATOR
Intervention: Fixed combination dorzolamide-timolol (FCDT)
Number of subjects: 30
Study 17407624 — intervention group
Group type: EXPERIMENTAL
Intervention: Both FCBT and FCDT
Number of subjects: 30
Study 15778167 — intervention group
Group type: EXPERIMENTAL
Intervention: Women take PRIDE program
Number of subjects: 457
Study 15778167 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 457
Study 11498263 — intervention group
Group type: EXPERIMENTAL
Intervention: T cells producing interferon‐gamma (IFN‐gamma)
Number of subjects: 13
Study 11498263 — intervention group
Group type: EXPERIMENTAL
Intervention: T cells producing interleukin (IL)‐4
Number of subjects: 13
Study 9711427 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil therapy for 12 weeks
Number of subjects: 27
Study 8040675 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 20 mg/d orally
Number of subjects: 182
Study 8040675 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA 1 g/d orally
Number of subjects: 182
Study 8040675 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen after MPA
Number of subjects: 182
Study 8040675 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA after Tamoxifen
Number of subjects: 182
Study 2689895 — intervention group
Group type: EXPERIMENTAL
Intervention: Single basal immunofluorometric (IFMA) TSH measurement
Number of subjects: 103
Study 2689895 — intervention group
Group type: COMPARATOR
Intervention: TRH test with RIA‐TSH measurements
Number of subjects: 103
Study 2689895 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal TSH measurement
Number of subjects: 103
Study 2689895 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of TT4 and/or FT4I
Number of subjects: 103
Study 2689895 — intervention group
Group type: EXPERIMENTAL
Intervention: Substitution therapy with thyroxine
Number of subjects: 103
Study 2689895 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐yr follow‐up of patients with subclinical thyroid dysfunction
Number of subjects: 103
Study 791472 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of fluorouracil, methyl‐CCNU, and vincristine
Number of subjects: 91
Study 791472 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil alone
Number of subjects: 91
Study 30098028 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study 30098028 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study 27208331 — intervention group
Group type: EXPERIMENTAL
Intervention: D/N‐AP
Number of subjects: 20
Study 27208331 — intervention group
Group type: EXPERIMENTAL
Intervention: E/N‐AP
Number of subjects: 20
Study 27208331 — intervention group
Group type: COMPARATOR
Intervention: SAP
Number of subjects: 20
Study 24632426 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective pulmonary perfusion (sPP) with venous blood at 2°C, 4 l
Number of subjects: 59
Study 24632426 — intervention group
Group type: COMPARATOR
Intervention: Standard cardiopulmonary bypass (CPB)
Number of subjects: 59
Study 22856459 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification program (LMP) involving individual and group sessions
Number of subjects: 301
Study 22856459 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification program (LMP)
Number of subjects: 301
Study 19857367 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 g Resistant Starch (RS)
Number of subjects: 20
Study 19857367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17921377 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose and 2.4 g amino acid kg(‐1) d(‐1)
Number of subjects: 15
Study 17921377 — intervention group
Group type: COMPARATOR
Intervention: Glucose only (control group)
Number of subjects: 15
Study 16076947 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvisomant (10 mg/d)
Number of subjects: 53
Study 11966672 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg moclobemide coadministration with 40 mg omeprazole
Number of subjects: 16
Study 11966672 — intervention group
Group type: COMPARATOR
Intervention: 40 mg omeprazole alone
Number of subjects: 16
Study 10566525 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient intra‐anal electromyographic biofeedback training
Number of subjects: 36
Study 10566525 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback training plus intrarectal balloon training
Number of subjects: 36
Study 10566525 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback training plus home training
Number of subjects: 36
Study 10566525 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback training, balloon training, and home training
Number of subjects: 36
Study 8904367 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing hats and masks in ultraclean airflow theatres
Number of subjects: 0
Study 8904367 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing balloon-cotton clothing
Number of subjects: 0
Study 8904367 — intervention group
Group type: COMPARATOR
Intervention: Not wearing hats or masks in ultraclean airflow theatres
Number of subjects: 0
Study 8904367 — intervention group
Group type: COMPARATOR
Intervention: Wearing a hat but no mask in ultraclean airflow theatres
Number of subjects: 0
Study 8904367 — intervention group
Group type: COMPARATOR
Intervention: Wearing a mask but no hat in ultraclean airflow theatres
Number of subjects: 0
Study 8904367 — intervention group
Group type: COMPARATOR
Intervention: Theoretical bacterial inoculum in conventional theatres or ultraclean theatres without hat or mask or wearing balloon-cotton clothing
Number of subjects: 0
Study 2032513 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 20
Study 2032513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7137540 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg bupivacaine
Number of subjects: 20
Study 7137540 — intervention group
Group type: COMPARATOR
Intervention: 4 mg/kg prilocaine
Number of subjects: 20
Study 31529008 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal mesh hysteropexy
Number of subjects: 183
Study 31529008 — intervention group
Group type: COMPARATOR
Intervention: Vaginal hysterectomy with uterosacral ligament suspension
Number of subjects: 183
Study 28336284 — intervention group
Group type: EXPERIMENTAL
Intervention: Food supplementation with carotenoids (5mg of Lutein and 1mg of Zeaxanthin)
Number of subjects: 126
Study 28336284 — intervention group
Group type: COMPARATOR
Intervention: No carotenoid supplementation (control group)
Number of subjects: 126
Study 27485297 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (225 min/week) in ALPHA trial
Number of subjects: 720
Study 27485297 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (300 min/week) in BETA trial
Number of subjects: 720
Study 27485297 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (150 min/week) in BETA trial
Number of subjects: 720
Study 27485297 — intervention group
Group type: COMPARATOR
Intervention: Control group (no activity) in ALPHA trial
Number of subjects: 720
Study 27485297 — intervention group
Group type: COMPARATOR
Intervention: Control group (no activity) in BETA trial
Number of subjects: 720
Study 24665578 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine concentrations of 1 mg/mL
Number of subjects: 160
Study 24665578 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine concentrations of less than 2 mg/mL
Number of subjects: 160
Study 24665578 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine concentrations
Number of subjects: 160
Study 24665578 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-induced stress test
Number of subjects: 160
Study 24665578 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine bronchial provocation test
Number of subjects: 160
Study 22926408 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl (100-μg bolus)
Number of subjects: 60
Study 22926408 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 60
Study 19817958 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) with artesunate
Number of subjects: 74
Study 19817958 — intervention group
Group type: COMPARATOR
Intervention: Placebo with artesunate
Number of subjects: 74
Study 17332612 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg/d)
Number of subjects: 8
Study 17332612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 15657908 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of MRSI and MRI data
Number of subjects: 24
Study 15657908 — intervention group
Group type: COMPARATOR
Intervention: MRSI data alone
Number of subjects: 24
Study 15657908 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of water intensities to the data set
Number of subjects: 24
Study 11888968 — intervention group
Group type: EXPERIMENTAL
Intervention: Water seal
Number of subjects: 68
Study 11888968 — intervention group
Group type: COMPARATOR
Intervention: Suction
Number of subjects: 68
Study 9468365 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir, lamivudine, and zidovudine (triple combination treatment)
Number of subjects: 33
Study 9468365 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir monotherapy (initial treatment before adding lamivudine and zidovudine)
Number of subjects: 33
Study 8521898 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thyrotropin-releasing hormone (TRH) 200 micrograms
Number of subjects: 16
Study 8521898 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 16
Study 2222550 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release propranolol (160 mg)
Number of subjects: 12
Study 2222550 — intervention group
Group type: COMPARATOR
Intervention: Conventional propranolol tablet (80 mg)
Number of subjects: 12
Study 2222550 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release propranolol
Number of subjects: 12
Study 2222550 — intervention group
Group type: COMPARATOR
Intervention: Conventional propranolol tablet
Number of subjects: 12
Study 7013310 — intervention group
Group type: EXPERIMENTAL
Intervention: Verrumal® (salicylic acid-containing product on a fluorouracil basis)
Number of subjects: 60
Study 7013310 — intervention group
Group type: COMPARATOR
Intervention: Placebo (without fluorouracil and without salicylic acid)
Number of subjects: 60
Study 31580129 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group received patients' mean ratings of their own health states before providing valuations.
Number of subjects: 155
Study 31580129 — intervention group
Group type: COMPARATOR
Intervention: Control group received patients' mean ratings of their own health states after providing valuations.
Number of subjects: 155
Study 29882696 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol post-conditioning (Cp 1.2 µg/mL)
Number of subjects: 60
Study 29882696 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (0.5-2%)
Number of subjects: 60
Study 29098740 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncontact low-frequency ultrasound (NLFU) treatment
Number of subjects: 0
Study 29098740 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 0
Study 25880911 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-setting (GS)
Number of subjects: 75
Study 25880911 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-setting with mentoring (GM)
Number of subjects: 75
Study 25880911 — intervention group
Group type: COMPARATOR
Intervention: Control (IC)
Number of subjects: 75
Study 25880911 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-setting (GS) and Goal-setting with mentoring (GM) combined
Number of subjects: 75
Study 23760223 — intervention group
Group type: EXPERIMENTAL
Intervention: Transpalpebral electrotherapy (n = 12), applied for 5 consecutive days with two sessions per day, each session including 8 spots (40 sec/spot) around the eye globe, current applied varied between 150 and 220 μA.
Number of subjects: 22
Study 23760223 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 10).
Number of subjects: 22
Study 21900084 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D
Number of subjects: 1761
Study 21900084 — intervention group
Group type: COMPARATOR
Intervention: Defibrillator-only
Number of subjects: 1761
Study 19593208 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 217
Study 19593208 — intervention group
Group type: COMPARATOR
Intervention: CYP2C9*1*3
Number of subjects: 217
Study 19593208 — intervention group
Group type: COMPARATOR
Intervention: CYP2C9*3
Number of subjects: 217
Study 20209127 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive framing over 10 years (the number escaping CVD per 1000)
Number of subjects: 1528
Study 20209127 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative framing over 10 years (the number that will have CVD)
Number of subjects: 1528
Study 20209127 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative framing per year over 10 years
Number of subjects: 1528
Study 20209127 — intervention group
Group type: EXPERIMENTAL
Intervention: All presentations shown to participants
Number of subjects: 1528
Study 15694559 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine b.i.d. (twice daily)
Number of subjects: 243
Study 15694559 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine t.i.d. (three times daily)
Number of subjects: 243
Study 15694559 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine b.i.d.
Number of subjects: 243
Study 15694559 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine t.i.d.
Number of subjects: 243
Study 15694559 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine b.i.d. and t.i.d.
Number of subjects: 243
Study 12413995 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal-stimulation regimen (clomiphene citrate and gonadotropins)
Number of subjects: 55
Study 12413995 — intervention group
Group type: COMPARATOR
Intervention: Standard long GnRH agonist (GnRH-a)-gonadotropin stimulation
Number of subjects: 55
Study 12413995 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal-stimulation regimen with ganirelix
Number of subjects: 55
Study 9856877 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon‐aminocaproic acid (EACA) 100 mg/kg at cannulation followed by 25 mg/kg/h for 72 hours
Number of subjects: 29
Study 9856877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 9856877 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon‐aminocaproic acid (EACA)
Number of subjects: 29
Study 7601182 — intervention group
Group type: EXPERIMENTAL
Intervention: Orchiectomy plus nilutamide (anandron)
Number of subjects: 0
Study 7601182 — intervention group
Group type: COMPARATOR
Intervention: Orchiectomy plus placebo
Number of subjects: 0
Study 2146067 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of isophane (NPH) insulin
Number of subjects: 7
Study 2146067 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous injection of isophane (NPH) insulin
Number of subjects: 7
Study 147656 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive containing cyproterone acetate
Number of subjects: 3
Study 147656 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive containing d-norgestrel
Number of subjects: 3
Study 147656 — intervention group
Group type: COMPARATOR
Intervention: Control group (without hormonal medication)
Number of subjects: 3
Study 12469457 — intervention group
Group type: EXPERIMENTAL
Intervention: Uninterrupted enteral nutrition (Group A)
Number of subjects: 40
Study 12469457 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutritional support (Group B)
Number of subjects: 40
Study 31085131 — intervention group
Group type: EXPERIMENTAL
Intervention: High galectin-3 and low HDL-C
Number of subjects: 2970
Study 30267385 — intervention group
Group type: EXPERIMENTAL
Intervention: Opicinumab (anti-LINGO-1; BIIB033)
Number of subjects: 39
Study 30267385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 27165652 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity and fall prevention intervention (30 groups) involving written information, fall risk assessment and prevention advice, a pedometer-based physical activity tracker, and telephone-based health coaching.
Number of subjects: 60
Study 27165652 — intervention group
Group type: COMPARATOR
Intervention: Healthy eating intervention (30 groups) involving written information and telephone-based dietary coaching.
Number of subjects: 60
Study 27165652 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity and fall prevention intervention
Number of subjects: 60
Study 27165652 — intervention group
Group type: COMPARATOR
Intervention: Healthy eating intervention
Number of subjects: 60
Study 24877155 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticocancellous bone block allograft (test group)
Number of subjects: 16
Study 24877155 — intervention group
Group type: COMPARATOR
Intervention: Autologous bone block from chin area (control group)
Number of subjects: 16
Study 24877155 — intervention group
Group type: EXPERIMENTAL
Intervention: Both procedures (test and control)
Number of subjects: 16
Study 23327028 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine‐‐fentanyl
Number of subjects: 60
Study 23327028 — intervention group
Group type: COMPARATOR
Intervention: Nalbuphine‐‐propofol
Number of subjects: 60
Study 19741029 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) intervention (n = 21)
Number of subjects: 41
Study 19741029 — intervention group
Group type: COMPARATOR
Intervention: Routine care condition (n = 20)
Number of subjects: 41
Study 19741029 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) intervention
Number of subjects: 41
Study 19808268 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 5010
Study 15667429 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (mean dosage 16.2 +/- 4.8 mg/day)
Number of subjects: 114
Study 15667429 — intervention group
Group type: COMPARATOR
Intervention: Clozapine (mean dosage 209 +/- 91 mg/day)
Number of subjects: 114
Study 15667429 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 114
Study 11907310 — intervention group
Group type: EXPERIMENTAL
Intervention: Visible light cure (Triad VLC)
Number of subjects: 50
Study 11907310 — intervention group
Group type: COMPARATOR
Intervention: Autopolymerizing (Orthoresin)
Number of subjects: 50
Study 9934940 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal vasopressin (20 IU before bedtime and after awakening)
Number of subjects: 26
Study 9934940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 8748052 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized aerobic training at ventilatory threshold for 3 months
Number of subjects: 9
Study 8748052 — intervention group
Group type: COMPARATOR
Intervention: Control group (9 asthmatic children)
Number of subjects: 9
Study 2189869 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam treatment
Number of subjects: 10
Study 2189869 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 10